• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Soleno Therapeutics Inc.

    9/5/24 6:37:11 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SLNO alert in real time by email
    SC 13G 1 ea0213665-13gvivo_soleno.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.       )*

     

    Soleno Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    834203309

    (CUSIP Number)

     

    August 27, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.  

    NAMES OF REPORTING PERSONS  

     

    Vivo Opportunity Fund Holdings, L.P.

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ☐        (b)   ☒

    3.  

    SEC USE ONLY

     

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION  

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
       5.   

    SOLE VOTING POWER

     

    6,291,851 (1)

       6.  

    SHARED VOTING POWER

     

    0

       7.  

    SOLE DISPOSITIVE POWER

     

    6,291,851 (1)

       8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,291,851 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    16.2% (2)

    12.  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The shares of common stock, $0.001 par value (the “Common Stock”) of Soleno Therapeutics, Inc. (the “Issuer”) are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

    (2)The percent of class was calculated based upon 38,871,594 shares of Common Stock of the Issuer outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 7, 2024.

     

    2

     

     

    1.  

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)    ☐       (b)   ☒

    3.  

    SEC USE ONLY

     

     

    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
       5.  

    SOLE VOTING POWER

     

    6,291,851 (1)

       6.  

    SHARED VOTING POWER

     

    0

       7.  

    SOLE DISPOSITIVE POWER

     

    6,291,851 (1)

       8.  

    SHARED DISPOSITIVE POWER

     

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,291,851 (1)

    10.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES    ☐

     

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    16.2% (2)

    12.  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)The shares of Common Stock of the Issuer are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
    (2)The percent of class was calculated based upon 38,871,594 shares of Common Stock of the Issuer outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

    3

     

     

    Explanatory Statement

     

    The Reporting Persons initially reported their beneficial ownership of the Issuer on a Schedule 13G filed with the SEC on May 15, 2023 and subsequently reported their beneficial ownership on a Schedule 13D originally filed with the SEC on June 1, 2023, as amended on October 11, 2023 and May 1, 2024 (the “Schedule 13D”). Pursuant to Rule 13d-1(h), the Reporting Persons are eligible to again report their beneficial ownership of shares of Common Stock of the Issuer on a Schedule 13G, and this Schedule 13G shall operate as an amendment to the Schedule 13D.

     

    Item 1. Issuer      
         
      (a) Name of Issuer:      
         
        Soleno Therapeutics, Inc. (the “Issuer”)      
         
      (b) Address of Issuer’s Principal Executive Offices:      
         
        203 Redwood Shores Pkwy, Suite 500
    Redwood City, CA 94065      
         
    Item 2. Filing Person      
         
      (a) – (c) Name of Persons Filing; Address; Citizenship:      

     

      (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and
         
      (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301.

     

      (d) Title of Class of Securities:      
         
        Common Stock, par value $0.001 per share (“Common Stock”).       
         
      (e) CUSIP Number: 

    834203309      

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:   

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act;
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act;
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act;
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
           
      (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

     

    4

     

     

      (j) ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.Ownership.

     

      (a) and (b) 

    Amount beneficially owned:

     

    The information set forth in rows 5 through 11 of the cover pages is incorporated by reference into this Item 4.  

     

    (c)Number of shares as to which such person has:

     

    Reporting Person  Sole
    Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Percentage of
    Common Stock
    Outstanding
     
    Vivo Opportunity Fund Holdings, L.P.   6,291,851    0    6,291,851    0    16.2%*
    Vivo Opportunity, LLC   6,291,851    0    6,291,851    0    16.2%*

     

    *The percent of class was calculated based upon 38,871,594 shares of Common Stock of the Issuer outstanding as of August 2, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.  

    Not applicable.   
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.      
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.  

    Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.  

    Not applicable.      
       
    Item 9. Notice of Dissolution of Group.  

    Not applicable.      
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 5, 2024

     

    VIVO OPPORTUNITY FUND HOLDINGS, L.P,  
         
    By: Vivo Opportunity, LLC  
    Its: General Partner  
         
    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  
         
    VIVO OPPORTUNITY, LLC  
         
    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title: Managing Member  

     

    6

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    99.1Joint Filing Statement

     

     

    7

     

     

    Get the next $SLNO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLNO

    DatePrice TargetRatingAnalyst
    8/20/2025$123.00Overweight
    Wells Fargo
    6/23/2025$110.00Buy
    TD Cowen
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    5/10/2024$72.00Outperform
    Robert W. Baird
    2/5/2024$93.00Overweight
    Piper Sandler
    More analyst ratings

    $SLNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    9/28/23 3:45:22 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Soleno Therapeutics with a new price target

    Wells Fargo initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $123.00

    8/20/25 9:01:56 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TD Cowen initiated coverage on Soleno Therapeutics with a new price target

    TD Cowen initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $110.00

    6/23/25 8:09:37 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Stifel resumed coverage on Soleno Therapeutics with a new price target

    Stifel resumed coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $74.00

    3/5/25 7:44:16 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2025.From approval on March 26, 2025 through June 30, 2025, Soleno reports: 646 patient start forms received295 unique prescribers of VYKAT XROver 100 million lives covered Announced submission and validation of Market

    8/6/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET

    REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 6, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Con

    7/28/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

    REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price. The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting disc

    7/10/25 9:07:23 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hirano Patricia C sold $316,971 worth of shares (3,830 units at $82.76), decreasing direct ownership by 22% to 13,206 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    7/3/25 4:41:13 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Officer Hirano Patricia C exercised 266 shares at a strike of $44.25 and sold $22,410 worth of shares (266 units at $84.25) (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    6/26/25 6:04:57 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Volck Birgitte was granted 3,991 shares, increasing direct ownership by 29% to 17,536 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    6/9/25 7:27:59 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    SEC Filings

    View All

    Soleno Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    8/18/25 6:54:43 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

    SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    8/14/25 4:35:25 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

    SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    8/14/25 1:07:20 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Set to Join Russell 3000® Index

    REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

    6/4/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Strengthens Leadership Team with Key Appointments

    REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

    1/24/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

    REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience. "Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board," said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno. "His impressive track record, including in rare diseases, will b

    8/16/23 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Financials

    Live finance-specific insights

    View All

    Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2025.From approval on March 26, 2025 through June 30, 2025, Soleno reports: 646 patient start forms received295 unique prescribers of VYKAT XROver 100 million lives covered Announced submission and validation of Market

    8/6/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET

    REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, August 6, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Con

    7/28/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

    REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 and Recent Corporate Highlights Announced U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). Announced launch and commencement of pati

    5/7/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 4:30:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

    SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 12:51:18 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care